515 related articles for article (PubMed ID: 9676461)
1. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
3. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
4. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
5. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
8. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
9. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.
Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Sandström P; Brismar TB; Smedby O; Lundberg P
Eur Radiol; 2012 Mar; 22(3):642-53. PubMed ID: 21984449
[TBL] [Abstract][Full Text] [Related]
10. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
[TBL] [Abstract][Full Text] [Related]
12. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study between Gd-BOPTA, a biliary excretion contrast medium, and Gd-DTPA in the magnetic resonance imaging of the rat liver].
Patrizio G; Pavone P; Cardone G; Pietroletti R; Passariello R; Tettamanti E; Musu C; Felder E
Radiol Med; 1990 May; 79(5):458-62. PubMed ID: 2359853
[TBL] [Abstract][Full Text] [Related]
15. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
[TBL] [Abstract][Full Text] [Related]
16. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
17. Chimeric mouse model for MRI contrast agent evaluation.
Mir FF; Tomaszewski RP; Shuboni-Mulligan DD; Mallett CL; Hix JML; Ether ND; Shapiro EM
Magn Reson Med; 2019 Jul; 82(1):387-394. PubMed ID: 30874333
[TBL] [Abstract][Full Text] [Related]
18. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
19. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
